174 related articles for article (PubMed ID: 38160071)
1. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
Boelaars K; Rodriguez E; Huinen ZR; Liu C; Wang D; Springer BO; Olesek K; Goossens-Kruijssen L; van Ee T; Lindijer D; Tak W; de Haas A; Wehry L; Nugteren-Boogaard JP; Mikula A; de Winde CM; Mebius RE; Tuveson DA; Giovannetti E; Bijlsma MF; Wuhrer M; van Vliet SJ; van Kooyk Y
Commun Biol; 2024 Apr; 7(1):430. PubMed ID: 38594506
[TBL] [Abstract][Full Text] [Related]
3. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
4. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
5. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
6. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
7. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
9. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
[TBL] [Abstract][Full Text] [Related]
10. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
12. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
15. Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer.
Wang J; Manni M; Bärenwaldt A; Wieboldt R; Kirchhammer N; Ivanek R; Stanczak M; Zippelius A; König D; Rodrigues Manutano N; Läubli H
Front Cell Dev Biol; 2022; 10():828916. PubMed ID: 35309936
[TBL] [Abstract][Full Text] [Related]
16. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
[TBL] [Abstract][Full Text] [Related]
17. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
18. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
Wielgat P; Czarnomysy R; Trofimiuk E; Car H
Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
[TBL] [Abstract][Full Text] [Related]
19. Targeting glyco-immune checkpoints for cancer therapy.
Manni M; Läubli H
Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
[No Abstract] [Full Text] [Related]
20. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]